Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Stage of breast cancer at diagnosis in New Zealand: impacts of socio-demographic factors, breast cancer screening and biology

Authors: Sanjeewa Seneviratne, Ross Lawrenson, Vernon Harvey, Reena Ramsaroop, Mark Elwood, Nina Scott, Diana Sarfati, Ian Campbell

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Examination of factors associated with late stage diagnosis of breast cancer is useful to identify areas which are amenable to intervention. This study analyses trends in cancer stage at diagnosis and impact of socio-demographic, cancer biological and screening characteristics on cancer stage in a population-based series of women with invasive breast cancer in New Zealand.

Methods

All women diagnosed with invasive breast cancer between 2000 and 2013 were identified from two regional breast cancer registries. Factors associated with advanced (stages III and IV) and metastatic (stage IV) cancer at diagnosis were analysed in univariate and multivariate models adjusting for covariates.

Results

Of the 12390 women included in this study 2448 (19.7 %) were advanced and 575 (4.6 %) were metastatic at diagnosis. Māori (OR = 1.86, 1.39-2.49) and Pacific (OR = 2.81, 2.03-3.87) compared with NZ European ethnicity, other urban (OR = 2.00, 1.37-2.92) compared with main urban residency and non-screen (OR = 6.03, 4.41-8.24) compared with screen detection were significantly associated with metastatic cancer at diagnosis in multivariate analysis. A steady increase in the rate of metastatic cancer was seen which has increased from 3.8 % during 2000-2003 to 5.0 % during 2010-2013 period (p = 0.042).

Conclusions

Providing equitable high quality primary care and increasing mammographic screening coverage needs to be looked at as possible avenues to reduce late-stage cancer at diagnosis and to reduce ethnic, socioeconomic and geographical disparities in stage of breast cancer at diagnosis in New Zealand.
Literature
1.
Ministry of Health: Cancer: New Registrations and Deaths 2012. In. Wellington: Ministry of Health; 2015.
2.
Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 suppl 7:vii11–9.CrossRefPubMed
3.
Hunter CP, Redmond CK, Chen VW, Austin DF, Greenberg RS, Correa P, et al. Breast cancer: factors associated with stage at diagnosis in black and white women. J Natl Cancer Inst. 1993;85(14):1129–37.CrossRefPubMed
4.
Otto SJ, Fracheboud J, Verbeek AL, Boer R, Reijerink-Verheij JC, Otten JD, et al. Mammography screening and risk of breast cancer death: a population-based case–control study. Cancer Epidemiol Biomark Prev. 2012;21(1):66–73.CrossRef
5.
Seneviratne S, Campbell I, Scott N, Shirley R, Lawrenson R. Impact of mammographic screening on ethnic and socioeconomic inequities in breast cancer stage at diagnosis and survival in New Zealand: a cohort study. BMC Public Health. 2015;15(1):46.PubMedCentralCrossRefPubMed
6.
Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003;163(1):49–56.CrossRefPubMed
7.
Farley TA, Flannery JT. Late-stage diagnosis of breast cancer in women of lower socioeconomic status: public health implications. Am J Public Health. 1989;79(11):1508–12.PubMedCentralCrossRefPubMed
8.
Wang Q, Li J, Zheng S, Li J-Y, Pang Y, Huang R, et al. Breast cancer stage at diagnosis and area-based socioeconomic status: a multicenter 10-year retrospective clinical epidemiological study in China. BMC Cancer. 2012;12(1):122.PubMedCentralCrossRefPubMed
9.
Flores YN, Davidson PL, Nakazono TT, Carreon DC, Mojica CM, Bastani R. Neighborhood socio-economic disadvantage and race/ethnicity as predictors of breast cancer stage at diagnosis. BMC Public Health. 2013;13(1):1061.PubMedCentralCrossRefPubMed
10.
Barry J, Breen N. The importance of place of residence in predicting late-stage diagnosis of breast or cervical cancer. Health Place. 2005;11(1):15–29.CrossRefPubMed
11.
Macleod U, Mitchell E, Burgess C, Macdonald S, Ramirez A. Risk factors for delayed presentation and referral of symptomatic cancer: evidence for common cancers. Br J Cancer. 2009;101:S92–S101.PubMedCentralCrossRefPubMed
12.
Ferrante JM, Gonzalez EC, Pal N, Roetzheim RG. Effects of physician supply on early detection of breast cancer. J Am Board Fam Pract. 2000;13(6):408–14.CrossRefPubMed
13.
Amey CH, Miller MK, Albrecht SL. The role of race and residence in determining stage at diagnosis of breast cancer. J Rural Health. 1997;13(2):99–108.CrossRefPubMed
14.
Davidson PL, Bastani R, Nakazono TT, Carreon DC. Role of community risk factors and resources on breast carcinoma stage at diagnosis. Cancer. 2005;103(5):922–30.CrossRefPubMed
15.
Hunter CP. Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in multiracial and multiethnic populations. Cancer. 2000;88(S5):1193–202.CrossRefPubMed
16.
Seneviratne S, Campbell I, Scott N, Shirley R, Peni T, Lawrenson R. Accuracy and completeness of the New Zealand Cancer Registry for staging of invasive breast cancer. Cancer Epidemiol. 2014;38(5):638–44.CrossRefPubMed
17.
Neave L, Harvey V, Benjamin C, Thompson P, Pellett O, Whitlock J, et al. The Auckland breast cancer register: a special project of the Auckland breast cancer study group. N Z Med J. 2003;116(1184):U648.PubMed
18.
19.
Salmond C, Crampton P, Atkinson J. NZDep2006: Index of Deprivation. Wellington: Department of Public Health, University of Otago; 2007.
20.
Statistics New Zealand. New Zealand: An Urban/Rural Profile Update. Wellington: Statistics New Zealand; 2006.
21.
Mandelblatt JS, Yabroff KR, Kerner JF. Equitable access to cancer services: A review of barriers to quality care. Cancer. 1999;86(11):2378–90.CrossRefPubMed
22.
American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.CrossRef
23.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–10.CrossRefPubMed
24.
Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13(1):63–72.PubMed
25.
Agresti A. Categorical data analysis. 2nd ed. New York: Wiley-Interscience; 2002.CrossRef
26.
Robson B, Harris R. Hauora: Màori Standards of Health IV. A study of the years 2000–2005. Wellington: Te Ròpù Rangahau Hauora a Eru Pòmare; 2007.
27.
Koay K, Schofield P, Jefford M. Importance of health literacy in oncology. Asia Pac J Clin Oncol. 2012;8(1):14–23.CrossRefPubMed
28.
Bish A, Ramirez A, Burgess C, Hunter M. Understanding why women delay in seeking help for breast cancer symptoms. J Psychosom Res. 2005;58(4):321–6.CrossRefPubMed
29.
Lannin DR, Mathews HF, Mitchell J, Swanson MS, Swanson FH, Edwards MS. Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer. Jama. 1998;279(22):1801–7.CrossRefPubMed
30.
Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334–57.CrossRefPubMed
31.
Brabyn L, Barnett AR: Population need and geographical access to general practitioners in rural New Zealand. 2004
32.
Malcolm L. Inequities in access to and utilisation of primary medical care services for Maori and low income New Zealanders. N Z Med J. 1996;109(1030):356–8.PubMed
33.
Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet. 1999;353(9159):1119–26.CrossRefPubMed
34.
Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367(21):1998–2005.CrossRefPubMed
35.
Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA. 2013;309(8):800–5.CrossRefPubMed
36.
Polednak AP. Increase in distant stage breast cancer incidence rates in US women aged 25–49 years, 2000–2011: the stage migration hypothesis. J Cancer Epidemiol. 2015;2015:710106.PubMedCentralCrossRefPubMed
37.
Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–92.CrossRefPubMed
38.
Kalager M, Zelen M, Langmark F, Adami H-O. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med. 2010;363(13):1203–10.CrossRefPubMed
39.
Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair‐Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer. Cancer. 2007;110(5):973–9.CrossRefPubMed
40.
Salmond CE, Crampton P. Development of New Zealand’s deprivation index (NZDep) and its uptake as a national policy tool. Can J Public Health. 2012;103(8 Suppl 2):S7–11.PubMed
Metadata
Title
Stage of breast cancer at diagnosis in New Zealand: impacts of socio-demographic factors, breast cancer screening and biology
Authors
Sanjeewa Seneviratne
Ross Lawrenson
Vernon Harvey
Reena Ramsaroop
Mark Elwood
Nina Scott
Diana Sarfati
Ian Campbell
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2177-5

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells

Research article

Overexpression of synuclein-γ predicts lack of benefit from radiotherapy for breast cancer patients

Research article

Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database

Research article

Macrophage phenotypic subtypes diametrically regulate epithelial-mesenchymal plasticity in breast cancer cells

Research article

Phase-specific and lifetime costs of cancer care in Ontario, Canada

Research article

The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits